Oxygen- and Sulphur-Containing Heterocyclic Compounds as Potential Anticancer Agents
- PMID: 35900713
- DOI: 10.1007/s12010-022-04099-w
Oxygen- and Sulphur-Containing Heterocyclic Compounds as Potential Anticancer Agents
Abstract
Oxygen- and sulphur-based heterocycles form the core structure of many biologically active molecules as well as U.S. FDA-approved drugs. Moreover, they possess broad range of biological activities, viz. anticancer, antiinflammatory, antioxidant, antitumour, antibacterial, antiviral, antidiabetic, anticonvulsant, anti-tubercular, analgesic, anti-leishmanial, antimalarial, antifungal, and anti-histaminic, Hence, O- and S-based heterocycles are gaining more attention in recent years on the road to the discovery of innovative anticancer drugs after the extensive investigation of nitrogen-based heterocycles as anticancer agents. Several attempts have been made to synthesize fused oxygen- and sulphur-based heterocyclic derivatives as joining one heterocyclic moiety with another may lead to improvement in the biological profile of a molecule. Humans have been cursed with cancer since long time. Despite the development of several heterocyclic anticancer medications such as 5-fluorouracil, doxorubicin, methotrexate, and daunorubicin, cure of cancer is difficult. Hence, researchers are trying to synthesize new fused/spiro heterocyclic molecules to discover novel anticancer drugs which may show promising anticancer effects with fewer side effects. Furthermore, fused heterocycles behave as DNA intercalating agents which have the ability to interact with DNA, leading to cell death thereby exerting anticancer effect. This review article highlights the synthesis and anticancer potentiality of oxygen- and sulphur-containing heterocyclic compounds covering the period from 2011 to 2021.
Keywords: Anticancer agents; Heterocyclic compounds; Oxygen-based; Sulphur-based.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Sulphur Containing Heterocyclic Compounds as Anticancer Agents.Anticancer Agents Med Chem. 2023;23(8):869-881. doi: 10.2174/1871520623666221221143918. Anticancer Agents Med Chem. 2023. PMID: 36545721 Review.
-
Heterocyclic Compounds: Importance in Anticancer Drug Discovery.Anticancer Agents Med Chem. 2022;22(19):3196-3207. doi: 10.2174/1871520622666220404082648. Anticancer Agents Med Chem. 2022. PMID: 35379130
-
Nitrogen-Containing Heterocycles as Anticancer Agents: An Overview.Anticancer Agents Med Chem. 2020;20(18):2150-2168. doi: 10.2174/1871520620666200705214917. Anticancer Agents Med Chem. 2020. PMID: 32628593 Review.
-
Role of sulphur-heterocycles in medicinal chemistry: An update.Eur J Med Chem. 2019 Oct 15;180:486-508. doi: 10.1016/j.ejmech.2019.07.043. Epub 2019 Jul 15. Eur J Med Chem. 2019. PMID: 31330449 Review.
-
A Comprehensive Review of N-Heterocycles as Cytotoxic Agents.Curr Med Chem. 2016;23(38):4338-4394. doi: 10.2174/0929867323666160809093930. Curr Med Chem. 2016. PMID: 27516198 Review.
Cited by
-
Seleno-Warfare against Cancer: Decoding Antitumor Activity of Novel Acylselenoureas and Se-Acylisoselenoureas.Pharmaceutics. 2024 Feb 14;16(2):272. doi: 10.3390/pharmaceutics16020272. Pharmaceutics. 2024. PMID: 38399326 Free PMC article.
-
FDA-approved heterocyclic molecules for cancer treatment: Synthesis, dosage, mechanism of action and their adverse effect.Heliyon. 2023 Dec 5;10(1):e23172. doi: 10.1016/j.heliyon.2023.e23172. eCollection 2024 Jan 15. Heliyon. 2023. PMID: 38163206 Free PMC article. Review.
-
Garlicnin B1, an Active Cyclic Sulfide from Garlic, Exhibits Potent Anti-Inflammatory and Anti-Tumor Activities.Antioxidants (Basel). 2023 Apr 3;12(4):869. doi: 10.3390/antiox12040869. Antioxidants (Basel). 2023. PMID: 37107245 Free PMC article.
References
-
- Sachdeva, H., Mathur, J., & Guleria, A. (2020). Indole derivatives as potential anticancer agents: A review. Journal of the Chilean Chemical Society, 65(3), 4900–4907. - DOI
-
- Pearce, S. (2017) The importance of heterocyclic compounds in anti-cancer drug design. Drug Discovery, 67.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources